LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

Kodu・Aktsiate loetelu・Novo Nordisk A-S

Novo Nordisk A-S

Suletud

Sektor Tervishoid

131.05 0.18

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

130.75

Max

131.39

Põhinäitajad
By Trading Economics
Sissetulek	-5.4B 20B
Müük	2.7B 68B
P/E Sektori keskmine	49.94 103.001
Aktsiakasum	4.49
Kasumimarginaal	29.459
EBITDA	-1.2B 36B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+10.38 upside

Turustatistika
By TradingEconomics
Turukapital	711M 471B
Eelmine avamishind	130.87
Eelmine sulgemishind	131.05

Uudiste sentiment

By Acuity

100%

331 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

130.53 / 134.62 Toetus ja vastupanu

Novo Nordisk A-S Graafik

Seotud uudised

7. aug 2024, 10:13 UTC

Tulu

Novo Nordisk's Wegovy Sales Disappoint -- 2nd Update

7. aug 2024, 06:58 UTC

Tulu

Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge -- Update

7. aug 2024, 06:10 UTC

Tulu

Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge

3. sept 2024, 11:09 UTC

Peamised uudised

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com

27. aug 2024, 05:30 UTC

Peamised uudised

Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com

14. aug 2024, 12:01 UTC

Market Talk

Tulu

Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk

9. aug 2024, 11:30 UTC

Peamised uudised

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ

9. aug 2024, 07:30 UTC

Market Talk

Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk

8. aug 2024, 15:44 UTC

Peamised uudised

Tulu

Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ

8. aug 2024, 11:36 UTC

Market Talk

Tulu

Novo Nordisk's Share-Price Weakness Provides an Opportunity -- Market Talk

8. aug 2024, 07:16 UTC

Market Talk

Tulu

Novo Nordisk's Share-Price Drop Provides Buying Opportunity -- Market Talk

7. aug 2024, 20:30 UTC

Peamised uudised

Eli Lilly Reports Earnings Thursday Amid a Stock Slump. Here's What to Expect. -- Barrons.com

7. aug 2024, 16:39 UTC

Tulu

Novo Nordisk's Wegovy Sales Disappoint -- Update

7. aug 2024, 15:30 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Novo Nordisk's Wegovy Sales Disappoint -- WSJ

7. aug 2024, 14:22 UTC

Peamised uudised

Tulu

It Isn't Time to Worry About Wegovy Yet -- Heard on the Street -- WSJ

7. aug 2024, 12:28 UTC

Market Talk

Tulu

Novo Nordisk's Core Products Disappoint -- Market Talk

7. aug 2024, 12:04 UTC

Tulu

Novo Nordisk Execs Were Speaking on a Call After 2Q Earnings

7. aug 2024, 11:34 UTC

Tulu

Novo Nordisk US Head: As Wegovy Volumes Go Up, Prices Will Come Down

7. aug 2024, 11:34 UTC

Tulu

Novo Nordisk CEO: When You Move Into New Sales Channels it Comes With a Discount

7. aug 2024, 11:34 UTC

Tulu

Novo Nordisk CEO: Wegovy Now Covered in 20 States Through Medicaid

7. aug 2024, 11:05 UTC

Market Talk

Tulu

Novo Nordisk Delivers Messy Quarter as Wegovy Misses The Mark -- Market Talk

7. aug 2024, 10:55 UTC

Tulu

Stock Market Madness Highlights This Problem for -2-

7. aug 2024, 10:55 UTC

Tulu

Stock Market Madness Highlights This Problem for Novo Nordisk and Super Micro. And 5 Other Things to Know Today. -- Barrons.com

7. aug 2024, 09:07 UTC

Tulu

Kuumad aktsiad

Stocks to Watch Wednesday: Super Micro, Rivian, Airbnb -- WSJ

7. aug 2024, 08:55 UTC

Peamised uudised

These Stocks Are Moving the Most Today: Super Micro, Lumen, Airbnb, Rivian, Fortinet, Upstart, Disney, and More -- Barrons.com

7. aug 2024, 07:32 UTC

Market Talk

Tulu

Novo Nordisk Wegovy Sales Disappoint -- Market Talk

7. aug 2024, 05:45 UTC

Tulu

Novo Nordisk Declares Interim Dividend of DKK3.50

7. aug 2024, 05:44 UTC

Tulu

Novo Nordisk 2Q Gross Margin 84.9% Vs 85.5%, Op Margin 38.1% Vs 44.0%

7. aug 2024, 05:40 UTC

Tulu

Novo Nordisk 2Q Wegovy Drug Sales DKK11.66B Vs DKK7.52B

7. aug 2024, 05:38 UTC

Tulu

Novo Nordisk: Sales Growth Has Resulted in Periodic Supply Constraints, Related Drug Shortage Notifications

Võrdlus sarnastega

Hinnamuutus

Novo Nordisk A-S Prognoos

Hinnasiht

By TipRanks

10.38% tõus

12 kuu keskmine prognoos

Keskmine 144.75 USD 10.38%

Kõrge 166 USD

Madal 82.5 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Novo Nordisk A-S 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Novo Nordisk A-S aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

130.53 / 134.62Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

331 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.